{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-252194","form_type":"8-K","ticker":"CPRX","cik":"0001369568","company_name":"CATALYST PHARMACEUTICALS, INC.","filed_at":"2024-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.272283+00:00","generated_at":"2026-05-30T04:24:26.724546+00:00","sec_items":["8.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Catalyst Pharma Q3 revenue $128.7M (+25% YoY); GAAP EPS $0.35; raises FY guidance","bullets":["Total revenue $128.7M, up 25.3% YoY; GAAP net income $43.9M ($0.35 diluted).","Non-GAAP net income $71.1M ($0.57 diluted); cash and equivalents $442.3M.","FIRDAPSE net rev $79.3M (+19.7%); AGAMREE early launch $15.0M; FYCOMPA $32.1M.","Full-year 2024 total revenue guidance raised to $475-485M.","Q3 2023 GAAP net loss of $30.8M vs. current net income of $43.9M."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-252194","json":"https://secwatch.observer/filing/0001193125-24-252194.json","markdown":"https://secwatch.observer/filing/0001193125-24-252194.md","text":"https://secwatch.observer/filing/0001193125-24-252194.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1369568/000119312524252194/0001193125-24-252194-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1369568/000119312524252194/d882968d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T04:24:26.724546+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}